Table 2.
Univariate analyses for overall survival in patients with diffuse large B‐cell lymphoma treated with R‐CHOP (n = 120)
| Prognostic factor | HR | 95% CI | P‐valuea | |
|---|---|---|---|---|
| Age, years | ≤60 vs >60 | 1.718 | 0.85–3.45 | 0.129 |
| Gender | Female vs male | 1.621 | 0.76–3.44 | 0.209 |
| Performance status | <2 vs ≥2 | 5.876 | 2.57–13.42 | <0.001 |
| Ann Arbor stage | ≤2 vs >2 | 1.986 | 0.09–4.20 | 0.073 |
| LDH (U/L) | Normal vs abnormal | 1.385 | 0.68–2.78 | 0.362 |
| B symptom | (−) vs (+) | 1.914 | 0.85–4.27 | 0.113 |
| Extranodal site involvement | <2 vs ≥2 | 1.568 | 0.77–3.17 | 0.212 |
| IPI | <3 vs ≥3 | 1.980 | 0.98–3.98 | 0.055 |
| GCB type | GCB vs non‐GCB | 0.936 | 0.46–1.09 | 0.854 |
| Radiation therapy | (−) vs (+) | 1.185 | 0.48–2.88 | 0.709 |
| MET expression | (−) vs (+) | 0.289 | 0.08–0.94 | 0.041 |
| RON expression | (−) vs (+) | 0.505 | 0.17–1.44 | 0.201 |
| MET/RON | MET+ or RON+ vs MET− and RON− | 3.975 | 1.39–11.30 | 0.010 |
a
Cox univariate analysis. CI, confidence interval; GCB, germinal center B‐cell‐like; HR, hazard ratio; IPI, International Prognostic Index; LDH, lactate dehydrogenase; R‐CHOP, rituximab plus cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisolone cyclophosphamide.